The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

According to reports, the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression in the 2019 however, this was only allowed as a prescription ...

Kennedy Jr. was pressed to clarify his views on vaccines, abortion and public health priorities in the first of two senate ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other safe stocks to ...

The FDA first approved the Johnson & Johnson drug, called Spravato (esketamine), for some cases of depression in 2019, but it was only allowed to be prescribed alongside an oral antidepressant. After ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...